Canaccord lowered the firm’s price target on Privia Health to $37 from $41 and keeps a Buy rating on the shares. The firm updated itsestimates post 4Q results inline with 2024 guidance and lowered the price target based on 1.5x 2024 estimated Practice Collections; a 25% premium to a peer group of traditional healthcare services and tech-enabled value-based care companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRVA:
- Barclays starts health care facilities, managed care group with Neutral view
- Privia Health initiated with an Equal Weight at Barclays
- Privia Health price target lowered to $26 from $30 at TD Cowen
- Privia Health sees FY24 GAAP revenue down 3.5% to up 1% to $1.6B-$1.68B
- Privia Health reports Q4 non-GAAP EPS 15c, consensus 4c
